You are not currently logged in.
Access your personal account or get JSTOR access through your library or other institution:
Ceftazidime vs. Amoxicillin/Clavulanate in the Treatment of Severe Melioidosis
Y. Suputtamongkol, A. Rajchanuwong, W. Chaowagul, D. A. B. Dance, M. D. Smith, V. Wuthiekanun, A. L. Walsh, S. Pukrittayakamee and N. J. White
Clinical Infectious Diseases
Vol. 19, No. 5 (Nov., 1994), pp. 846-853
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4458144
Page Count: 8
Preview not available
An open, paired, randomized, controlled trial of high-dose parenteral ceftazidime (120 mg/[kg·d]) vs. amoxicillin/clavulanate (160 mg/[kg·d]) for the treatment of severe melioidosis was conducted in Ubon Ratchatani in northeastern Thailand. Of 379 patients enrolled in the study, 212 (56%) had culture-proven melioidosis; 106 patients were in each treatment group. The overall mortality rate (47%) was similar for both treatment groups. However, 4 of 75 surviving patients in the ceftazidime group compared with 16 of 69 surviving patients in the amoxicillin/clavulanate group were switched to the alternate regimen because of an unsatisfactory clinical response after ≥72 hours of treatment (P = .004). The overall therapeutic failure rate (i.e., treatment failure or death due to uncontrolled melioidosis) was significantly higher for the amoxicillin/clavulanate group than for the ceftazidime group (P = .02). Clinical and bacteriologic responses for successfully treated patients were similar in both groups, and both treatments were well tolerated. Parenteral amoxicillin/clavulanate is a safe and effective initial treatment, but parenteral ceftazidime remains the treatment of choice for severe melioidosis.
Clinical Infectious Diseases © 1994 Oxford University Press